We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Cardiovascular and Bone Health Outcomes After Oophorectomy in Postmenopausal Women Undergoing Benign Hysterectomy: Insights from a Population-Based Study

MedXY Editorial Team•Sep 8, 2026•Cardiology
cardiovascular riskhysterectomyoophorectomybone healthpostmenopausal

Highlight

  • Postmenopausal bilateral salpingo-oophorectomy during benign hysterectomy does not increase the risk of clinical cardiovascular or bone outcomes.
  • Oophorectomy is associated with a higher risk of diabetes and hypertension, conditions predisposing to cardiovascular diseases.
  • Women undergoing oophorectomy are more likely to initiate menopausal hormone therapy post-surgery.
  • Findings suggest potential benefits in retaining postmenopausal ovaries during benign hysterectomy to mitigate cardiovascular risk factors.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Subclinical Liver Disease as a Silent Driver of Cardiovascular Risk: Insights from a Large-Scale Prospective StudySubclinical liver disease, marked by steatosis, fibrosis, and functional impairment, independently and synergistically increases cardiovascular disease risk. Incorporating non-invasive liver biomarkers could enhance CVD risk prediction andSep 15, 2026Illuminating the Night: How Nighttime Light Exposure Impacts Cardiac Structure, Function, and Cardiovascular RiskNighttime light exposure over 3 lux is linked to adverse cardiac remodeling, subclinical functional decline, and increased cardiovascular events, partly mediated by shorter sleep duration, underscoring the importance of dark nights and sleeSep 15, 2026Menopausal Hormone Therapy and Cardiovascular Risk in Midlife Women with Vasomotor Symptoms: Insights from the SWAN StudyInitiation of menopausal hormone therapy during perimenopause or early postmenopause in women with vasomotor symptoms is associated with a reduced cardiovascular risk, especially among Black women and those starting therapy within 10 yearsSep 13, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Tropical Cyclones and Acute Coronary Syndromes: Unraveling the Cardiovascular Burden in Mainland China
A nationwide Chinese study reveals that exposure to tropical cyclones increases acute coronary syndrome risk by 14%, delays treatment times, and disproportionately affects vulnerable populations. Coordinated public health and clinical strat
Sep 12, 2026
Macrotroponin Complexes and Risk of Cardiovascular Events: Implications for Cardiac Troponin Testing in Population Risk StratificationMacrotroponin complexes commonly cause discordant cardiac troponin elevations in the general population, notably troponin I, without conferring increased cardiovascular risk, underscoring the need to recognize assay interference for accuratSep 11, 2026
Tocilizumab Reduces Major Cardiovascular Events Risk in Giant Cell Arteritis: Insights from a Nationwide French CohortA nationwide observational study reveals tocilizumab use in giant cell arteritis significantly lowers major adverse cardiovascular events compared to methotrexate, highlighting its potential cardiovascular benefits beyond inflammation contrSep 8, 2026